Texas Glutathione Recall: Third Pharmacy Pulls Vials Over Endotoxin

Centric Compounding (Houston, Texas) recalled six lots of injectable glutathione, Myer’s Cocktail, and Tri-Immune Boost on September 9, 2026, after testing found elevated bacterial endotoxin in the glutathione ingredient used to make them, according to the FDA recall notice published September 13. The vials reached patients nationwide by home delivery and through prescribers. Nine people reported fever, chills, chest pain, nausea or vomiting, headache, or malaise — the first patient reactions disclosed in a run of three Texas compounding pharmacy recalls in five weeks.

Safety callout — check your vial now. If you received a glutathione, Myer’s Cocktail, or Tri-Immune Boost injection supplied by Centric Compounding, find the lot number on the vial and compare it against the list below. If it matches, stop using the vial and discard it, and contact Centric at 833-777-6664. Seek emergency care for difficulty breathing, chest pain, fainting, throat or facial swelling, a rapidly spreading rash, or a sudden high fever after an infusion.

What Centric Compounding recalled

The recall covers six lots across three compounded injectable products, all 30 mL multi-dose vials:

Centric says it is contacting customers by email and arranging replacement. The FDA notice lists the consumer line as 833-777-6664 and info@centriccompounding.com, staffed Monday through Friday, 9am to 5pm Central.

What makes this recall different

Nine reported reactions, a first in the series

Neither August recall notice in the same product line disclosed any injury. Both were patient-level pulls issued on the strength of the pharmacies’ own endotoxin testing, not responses to harm. Centric’s notice reports events: nine cases of fever, chills, chest pain, nausea or vomiting, headache, or malaise.

Those counts come from the company, not a regulator, and the notice does not say whether any patient was hospitalised.

The root cause sits one step upstream

The August notices described elevated endotoxin found in finished vials. Centric names the cause a step earlier: the products “have been found to be compounded with a Glutathione API containing elevated endotoxin levels.”

That distinction changes the scope of the problem. A contaminated bulk drug substance is not one pharmacy’s process failure — every compounder that bought the same ingredient lot inherits the defect, and finished-vial testing only catches it batch by batch, after product shipped. Three recalls in five weeks, all involving compounded glutathione 200 mg/mL, is the pattern a shared ingredient problem would produce.

There is precedent. In 2019 the FDA warned compounders about L-glutathione from a single bulk vendor after seven patients reacted within minutes of an IV infusion, one of whom was hospitalised, with endotoxin measured at up to five times the limit. The lesson is the same now: for a compounded product with no approved manufacturer and no premarket review, the ingredient supply chain is the safety control.

Three Texas pharmacies, five weeks, one product

The first two are documented in Peptide Recall 2026: Glutathione Endotoxin Risk, 14 States. Centric is the third, and the first to involve a range of products rather than glutathione alone. Glutathione is a tripeptide, which is how a sterility defect in an IV vitamin blend lands on the peptide beat at all.

What the notice does and does not say

The risk statement in all three notices is the company’s own wording, repeated verbatim: “There is reasonable probability that injectable products with elevated endotoxin levels could cause significant medical events including fevers, hypotension, inflammatory reactions, anaphylactic shock and death.” That is a manufacturer’s assessment of a hazard, not a finding that those outcomes occurred.

What the notice does not say: which API supplier or lot is implicated, whether state boards were notified, whether the FDA inspected the facility, and what recall classification the agency assigns. Class I, II or III designations publish later and are the clearest public measure of how serious the agency judged the hazard. None of the three products is an FDA-approved drug; compounded glutathione is marketed off-label for skin brightening, detoxification and immune support without FDA review.

How to check whether your vial is affected

Your vial is affected only if its lot number appears above. Check the label, and if you never saw the vial — common when a clinic or med spa administers the infusion — ask which pharmacy supplied the product and which lot was used.

1. Stop using the product and quarantine the vial. Centric instructs consumers to discard affected vials.
2. Contact Centric Compounding at 833-777-6664 or info@centriccompounding.com to confirm whether your lot is covered and arrange replacement.
3. Report any reaction to your prescribing clinician and to FDA MedWatch (1-800-332-1088).

The 10-point compounding pharmacy verification checklist covers license status, state oversight and lot-level testing history before your next order. When the vial came from a clinic rather than a pharmacy counter, the same 503A/503B and inspection-history checks apply to that supply route. Nothing here involves a counterfeit product; the physical markers that separate a traced pharmacy supply from an untraceable one are in how to spot fake pens and vials.

FAQ

Which lots of Centric Compounding products were recalled?

Glutathione 200 mg/mL 30 mL: lots 062326:B, 070826:A and 072726:D. Myer’s Cocktail 30 mL: lots 070226:D and 072126:A. Tri-Immune Boost 30 mL: lot 071626:B. All six were recalled to the consumer level nationwide.

Was anyone hurt by the Centric Compounding recall?

Centric reported nine cases of fever, chills, chest pain, nausea or vomiting, headache, or malaise. The notice does not state whether any patient was hospitalised, and no regulator has confirmed a causal link.

Why did Centric Compounding recall its vials?

The company states the products were compounded using a glutathione active pharmaceutical ingredient containing elevated bacterial endotoxin levels — a raw-material failure rather than a finished-product finding.

Is this the same recall as the August glutathione recalls?

No. Three separate Texas pharmacies have now recalled compounded glutathione 200 mg/mL for elevated endotoxin: Victory Medical Center Pharmacy (August 5), Optimal Balance Pharmacy (August 19) and Centric Compounding (September 9). The lot numbers differ in each case, so check your vial against the right list.

What are the symptoms of an endotoxin reaction?

Fever, chills, severe headache, nausea, vomiting, rapid heartbeat and blood pressure changes, typically within minutes to a few hours of injection. Severe reactions include anaphylactic shock, difficulty breathing, chest pain, fainting, and throat or facial swelling, which require emergency care.

What to watch next

Three voluntary recalls in five weeks, all tracing to the same product and the same defect, is the kind of cluster that draws state board attention — 503A compounders answer primarily to state regulators, which is why states have become the practical front line of peptide oversight. Watch for a recall classification from the FDA, any action naming an API supplier, and whether the Texas State Board of Pharmacy opens an inspection file.

For the pattern of independent testing behind compounded and gray-market vials, see the 9,997-test dataset. For the broader sequence — the April reclassification, the July PCAC recommendations and what comes next — follow the 2026 FDA peptide regulatory timeline.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.